2. Signaling Pathways
  3. Anti-infection
  4. RSV
  5. RSV Inhibitor

RSV Inhibitor

RSV Inhibitors (66):

Cat. No. Product Name Effect Purity
  • HY-B0434
    Ribavirin
    		Inhibitor 99.80%
    Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.
  • HY-15455
    Roflumilast
    		Inhibitor 99.98%
    Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
  • HY-104032
    Ac-CoA Synthase Inhibitor1
    		Inhibitor 99.33%
    Ac-CoA Synthase Inhibitor1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 µM. Ac-CoA Synthase Inhibitor1 inhibits the respiratory syncytial virus (RSV).
  • HY-N0662
    Amentoflavone
    		Inhibitor 99.81%
    Amentoflavone (Didemethyl-ginkgetin) is a potent and orally active GABA(A) negative modulator. Amentoflavone also shows anti-inflammatory, antioxidative, anti-viral, anti-tumor, anti-radiation, anti-fungal, antibacterial activity. Amentoflavone induces apoptosis and cell cycle arrest at sub-G1 phase.
  • HY-126303C
    GS-443902 trisodium
    		Inhibitor 99.98%
    GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734).
  • HY-N12305
    4,5-O-Dicaffeoyl quinic acid methyl ester
    		Inhibitor
    4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratory syncytial virus (RSV) with an IC50 of 0.63 μg/mL and a CC50 of 118.68 μg/mL.
  • HY-109142
    Ziresovir
    		Inhibitor
    Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species.
  • HY-12983
    ALS-8112
    		Inhibitor 98.90%
    ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.
  • HY-P9944
    Palivizumab
    		Inhibitor 99.43%
    Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
  • HY-102038
    PC786
    		Inhibitor 99.24%
    PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM).
  • HY-112180
    Rilematovir
    		Inhibitor 98.00%
    Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
  • HY-146246
    EIDD-2749
    		Inhibitor 99.85%
    EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
  • HY-16727
    Presatovir
    		Inhibitor 99.94%
    Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC50 value of 0.43 nM.
  • HY-123475
    Sisunatovir
    		Inhibitor 99.08%
    Sisunatovir (RV521), an orally available inhibitor of the RSV protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
  • HY-12283
    Rostafuroxin
    		Inhibitor 98.00%
    Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na+,K+-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity.
  • HY-11097
    TMC353121
    		Inhibitor ≥98.0%
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
  • HY-12983A
    Lumicitabine
    		Inhibitor 99.78%
    Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
  • HY-145119AS
    Mindeudesivir hydrobromide
    		Inhibitor 99.46%
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
  • HY-P99756
    Nirsevimab
    		Inhibitor
    Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research.
  • HY-12993
    RSV604
    		Inhibitor 99.92%
    RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM).